Martin David Harp

The topical ophthalmic solution is preservative-free and includes dual lubricants—hyaluronic acid and hydroxypropyl methylcellulose—for patient comfort.

According to the company, this is the first and only single-use kit on the market that includes the diagnostic lens.

Additionally, the FDA approved a monthly dosing option for some patients who may benefit from resuming this dosing schedule across approved indications.

The procedure was conducted as part of the company’s ongoing phase 1 clinical trial.

The acquisition includes product candidates MELT-210, MELT-300, and MELT-400 based on the Zydis ODT (oral dissolving tablet) drug delivery platform.

CoTx-101 is intended for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

RUSH2A is an ongoing natural history study for patients with mutations in the USH2A gene causing Usher syndrome type 2A or nonsyndromic retinitis pigmentosa (RP).

Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by mutations in the BEST1 gene, leading to progressive vision loss and potentially blindness.

STAAR Surgical extends its merger timeline with Alcon, inviting third-party proposals to maximize stockholder value amid ongoing opposition from Broadwood Partners.

This resubmission follows the complete response letter (CRL) Outlook received in August 2025.

The BIM-IOL System is for the treatment of elevated IOP in patients with mild-to-moderate open-angle glaucoma (OAG) or ocular hypertension (OHT).

The company describes KSI-101 as a “novel, potent, and high-strength (100 mg/mL) antibody-based investigational therapy with a bispecific mechanism of action targeting both interleukin-6 (IL-6) and vascular endothelial growth factor (VEGF).”

OPGx-LCA5 is designed to address a form of Leber congenital amaurosis that results from biallelic mutations in the LCA5 gene, which encodes the lebercilin protein, the investigators explained.

PolyActiva and RareSight collaborate to create innovative therapies for rare pediatric retinal diseases, aiming to transform treatment and improve children's vision.

The trial is evaluating 4D-150 in patients with wet age-related macular degeneration (wet AMD).

The VITA Trial is a prospective pilot study on the VisiPlate Aqueous Shunt in patients with with open-angle glaucoma.

The EXTEND study is a 5-year follow-up of participants who received a single intravitreal injection of MCO-010 in a previously conducted phase 1/2a trial.

The trial will be evaluating AXPAXLI dosed every 6 months versus aflibercept (2 mg) dosed every 8 weeks in treatment-naïve wet AMD patients.

Under the terms of the agreement, 4DMT will grant Otsuka exclusive rights to develop and commercialize 4D-150 for retinal vascular diseases in Japan, China, Australia, and other Asia-Pacific markets.

The funding will support the completion of the clinical PoC of its AAVB-039 CELESTE study and the completion of the STELLA natural history study

Veligrotug is an intravenously delivered, anti-insulin-like growth factor-1 receptor (IGF-1R) antibody for the treatment of thyroid eye disease (TED).

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

NYRVANA is the first-in-human trial and is an open-label, multicenter, dose-escalation study investigating the safety, tolerability, and preliminary efficacy of a single intravitreal injection of SPVN20 over 6 months.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

To celebrate Ophthalmology Times' 50th anniversary, we asked leading experts what the practice would look like today had optical coherence tomography (OCT), one of the biggest innovations in the field, never been invented.

STAAR releases new date for shareholder meeting